2024
Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study
Kohut T, Tou A, Carr E, Xanthakos S, Arce‐Clachar A, Fawaz R, Valentino P, Panganiban J, Mouzaki M. Topiramate treatment of pediatric metabolic dysfunction–associated steatotic liver disease: A descriptive cohort study. Journal Of Parenteral And Enteral Nutrition 2024, 49: 308-313. PMID: 39720872, DOI: 10.1002/jpen.2722.Peer-Reviewed Original ResearchBody mass indexBody mass index z-scoreBaseline to 3Alanine aminotransferaseGlycated hemoglobinLifestyle modificationZ-scoreAlanine aminotransferase normalizationPatients aged <Weight loss medicationsAlanine aminotransferase levelsMild side effectsSerum alanine aminotransferaseObesity pharmacotherapyTopiramate treatmentPrimary treatmentLaboratory valuesOff-labelPediatric obesityMass indexTopiramateCohort studySingle agentPrimary outcomeLipid profileSix-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications
Chudzicka-Strugała I, Kubiak A, Banaszewska B, Wysocka E, Zwozdziak B, Siakowska M, Pawelczyk L, Duleba A. Six-month randomized, placebo controlled trial of synbiotic supplementation in women with polycystic ovary syndrome undergoing lifestyle modifications. Archives Of Gynecology And Obstetrics 2024, 311: 499-506. PMID: 39636391, PMCID: PMC11890239, DOI: 10.1007/s00404-024-07833-3.Peer-Reviewed Original ResearchPolycystic ovary syndromeIntensive lifestyle modificationPlacebo groupLifestyle modificationSynbiotic groupMetabolic aspects of polycystic ovary syndromeSynbiotic supplementationImprovement of hyperandrogenismMarkers of endotoxemiaLow-density lipoprotein cholesterolPlacebo-controlled trialReduction of BMILong-term administrationBody fat percentageLPS-binding proteinAdministration of synbioticsObese subjectsReduced LHTotal testosteronePlaceboLipoprotein cholesterolLaboratory aspectsLipid profileTotal cholesterolSix-monthsP21 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III ELATIVE® trial
Mayo M, Antunes N, Pedersen M, Tonev D, Shu J, Bowlus C, Kowdley K, Zein C, Levy C. P21 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III ELATIVE® trial. 2024, a22.2-a23. DOI: 10.1136/gutjnl-2024-basl.32.Peer-Reviewed Original ResearchCaloric restriction reduces trabecular bone loss during aging and improves bone marrow adipocyte endocrine function in male mice
Rinne C, Soultoukis G, Oveisi M, Leer M, Schmidt-Bleek O, Burkhardt L, Bucher C, Moussa E, Makhlouf M, Duda G, Saraiva L, Schmidt-Bleek K, Schulz T. Caloric restriction reduces trabecular bone loss during aging and improves bone marrow adipocyte endocrine function in male mice. Frontiers In Endocrinology 2024, 15: 1394263. PMID: 38904042, PMCID: PMC11188307, DOI: 10.3389/fendo.2024.1394263.Peer-Reviewed Original ResearchConceptsBone marrow adipose tissueTrabecular bone lossAged miceCaloric restrictionBone lossEndocrine profileMale C57BL6J miceCardio-metabolic diseasesTime of CRAge-matched littermatesBiochemical lipid profilesAssess bone microstructureFree food accessC57BL6J miceBone healthYoung miceContext of agingMale miceDietary interventionNutritional interventionAnatomical localizationLipid profileAdipogenic gene expressionBone dysfunctionTrabecular bone structureTHU-105 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III Elativetrial
Mayo M, Antunes N, Pedersen M, Tonev D, Shu J, Bowlus C, Kowdley K, Zein C, Levy C. THU-105 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III Elativetrial. Journal Of Hepatology 2024, 80: s312-s313. DOI: 10.1016/s0168-8278(24)01090-0.Peer-Reviewed Original ResearchIs Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer
Nassar A, Nie X, Zhang T, Yeung J, Norris P, He J, Ogura H, Babar M, Muldoon A, Libreros S, Chen L. Is Lipid Metabolism of Value in Cancer Research and Treatment? Part I- Lipid Metabolism in Cancer. Metabolites 2024, 14: 312. PMID: 38921447, PMCID: PMC11205345, DOI: 10.3390/metabo14060312.Peer-Reviewed Original ResearchMass spectrometryLipid metabolismTherapeutic efficacy of treatmentLipidomic studiesEfficacy of treatmentStudy of lipidsEmergence of lipidomicsLipid categoriesSpectrometryEnergy storageTumor microenvironmentPharmaceutical candidatesTherapeutic efficacyLipidomicsCancer patientsLipid profileCancer samplesCancerLarge-scale studiesCancer researchTargeted approachAlterationsDisease developmentCell growthMetabolismMachine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients
Hosseini K, Behnoush A, Khalaji A, Etemadi A, Soleimani H, Pasebani Y, Jenab Y, Masoudkabir F, Tajdini M, Mehrani M, Nanna M. Machine learning prediction of one-year mortality after percutaneous coronary intervention in acute coronary syndrome patients. International Journal Of Cardiology 2024, 409: 132191. PMID: 38777044, DOI: 10.1016/j.ijcard.2024.132191.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionLogistic regressionPost-PCI mortalityPrediction of one-year mortalityCoronary interventionPrediction of 1-year mortalityBody mass indexAcute coronary syndrome patientsOne-year mortalityIndividual-level assessmentsReceiver operating characteristic curveAcute coronary syndromeCoronary syndrome patientsTehran Heart CenterRates of comorbiditiesMass indexHigher ageSyndrome patientsCoronary syndromeHeart CenterFollow-upLipid profileU-shaped correlationPatientsCharacteristic curve
2023
A Polynesian-specific missense CETP variant alters the lipid profile
Moors J, Krishnan M, Sumpter N, Takei R, Bixley M, Cadzow M, Major T, Phipps-Green A, Topless R, Merriman M, Rutledge M, Morgan B, Carlson J, Zhang J, Russell E, Sun G, Cheng H, Weeks D, Naseri T, Reupena M, Viali S, Tuitele J, Hawley N, Deka R, McGarvey S, de Zoysa J, Murphy R, Dalbeth N, Stamp L, Taumoepeau M, King F, Wilcox P, Rapana N, McCormick S, Minster R, Merriman T, Leask M. A Polynesian-specific missense CETP variant alters the lipid profile. Human Genetics And Genomics Advances 2023, 4: 100204. PMID: 37250494, PMCID: PMC10209881, DOI: 10.1016/j.xhgg.2023.100204.Peer-Reviewed Original ResearchConceptsPopulation-specific genetic variantsGenomic studiesGenetic analysisFunction mutationsVariant altersGenetic determinantsGenetic variantsMinor alleleCETP deficiencyGenomicsHigher HDLLipid profileTraitsSequencingLow LDL-C levelsMutationsAllelesLDL-C levelsSerum lipid profileCopiesPolymorphismAssociatesLower LDLCardiovascular diseaseVariantsShort-term flaxseed oil, rich in omega 3, protects mice against metabolic damage caused by high-fat diet, but not inflammation
Nakandakari S, Gaspar R, Kuga G, Ramos C, Vieira R, Rios T, Muñoz V, Sant'ana M, Simabuco F, da Silva A, Moura L, Ropelle E, Pauli J, Cintra D. Short-term flaxseed oil, rich in omega 3, protects mice against metabolic damage caused by high-fat diet, but not inflammation. The Journal Of Nutritional Biochemistry 2023, 114: 109270. PMID: 36706930, DOI: 10.1016/j.jnutbio.2023.109270.Peer-Reviewed Original ResearchConceptsControl groupFood intakeAdipose tissueLong-term high-fat diet feedingHigh-fat diet feedingFlaxseed oilHigh-fat dietMesenteric adipose tissueFatty acid incorporationNeuronal signaling pathwaysInflammatory markersHF dietInflammatory effectsDiet feedingEarly inflammationHF groupLipid profileTNFα proteinProtective effectTriggers inflammationMetabolic disordersGlucose homeostasisBody weightInflammationHF consumptionChapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection
Balasubramanian P, Inzucchi S. Chapter 13 Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection. 2023, 337-363. DOI: 10.1016/b978-0-323-99991-5.00006-1.Peer-Reviewed Original ResearchSGLT2 inhibitorsType 2 diabetesSodium-glucose cotransporter 2 inhibitorsGlucose cotransporter 2 inhibitorsLarge cardiovascular outcome trialsInduction of glucosuriaRenal protective benefitsCardiovascular risk factorsGlucose-lowering medicationsCardiovascular outcome trialsCotransporter 2 inhibitorsClinical practice guidelinesMechanism of actionRenal benefitsCardiorenal benefitsDiabetes statusOutcome trialsBlood pressureChronic kidneyHeart failureRisk factorsLipid profileCardiovascular diseasePractice guidelinesBody weight
2022
Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
Shen M, Nargesi A, Nasir K, Bhatt DL, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States. Journal Of The American Heart Association 2022, 11: e026075. PMID: 36102276, PMCID: PMC9683659, DOI: 10.1161/jaha.122.026075.Peer-Reviewed Original ResearchConceptsLipid-Lowering TherapyIcosapent ethylCardiology/American Heart Association (ACC/AHA) guideline recommendationsNutrition Examination Survey dataAddition of ezetimibeUse of statinsClinical practice guidelinesCurrent statin usePopulation health outcomesConclusions SixCardiovascular outcomesStatin useClinical profileGuideline recommendationsLipid profileNational HealthPCSK9iNovel therapiesNovel agentsPractice guidelinesUS adultsAmerican CollegeStatinsHealth outcomesTherapyER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling
Hancock-Cerutti W, Wu Z, Xu P, Yadavalli N, Leonzino M, Tharkeshwar AK, Ferguson SM, Shadel GS, De Camilli P. ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling. Journal Of Cell Biology 2022, 221: e202106046. PMID: 35657605, PMCID: PMC9170524, DOI: 10.1083/jcb.202106046.Peer-Reviewed Original ResearchConceptsParkinson's diseasePD pathogenesisLeucine-rich repeat kinase 2 (LRRK2) G2019S mutationCGAS-STING pathwayAccumulation of lysosomesDNA-sensing cGAS-STING pathwayImmune activationLipid profileSTING signalingG2019S mutationAutosomal recessive Parkinson's diseaseRecessive Parkinson's diseaseModel human cell linesHuman cell linesCell linesPathogenesisLate endosomes/lysosomesDiseaseVPS13CEndosomes/lysosomesCurrent studyTransfer proteinActivationCellsPathwayMaternal urinary phthalate metabolites are associated with lipidomic signatures among pregnant women in Puerto Rico
Ashrap P, Aung M, Watkins D, Mukherjee B, Rosario-Pabón Z, Vélez-Vega C, Alshawabkeh A, Cordero J, Meeker J. Maternal urinary phthalate metabolites are associated with lipidomic signatures among pregnant women in Puerto Rico. Journal Of Exposure Science & Environmental Epidemiology 2022, 32: 384-391. PMID: 35075242, PMCID: PMC9124693, DOI: 10.1038/s41370-022-00410-3.Peer-Reviewed Original ResearchConceptsUrinary phthalate metabolitesPhthalate metabolitesPlasmenyl-phosphatidylcholinesPregnant womenPuerto Rico PROTECT cohortPhthalate exposureLipidomic profilesMaternal urinary phthalate metabolitesWeeks of pregnancyMetabolite biomarkersMetabolites of di-2-ethylhexyl phthalateChild health outcomesCirculating lipid concentrationsLipidomic markersShotgun lipidomicsFatty acid chainsLipidomic signaturePROTECT cohortLipid profileCell-to-cell signalingImpactThis studyPregnancyAcid chainsPlasma samplesHealth outcomesInhibition of high-fat diet–induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms
Wang X, Yang Y, Zhao D, Zhang S, Chen Y, Chen Y, Feng K, Li X, Han J, Iwakiri Y, Duan Y, Yang X. Inhibition of high-fat diet–induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms. Journal Of Biological Chemistry 2022, 298: 101561. PMID: 34998825, PMCID: PMC8814669, DOI: 10.1016/j.jbc.2022.101561.Peer-Reviewed Original ResearchConceptsHigh-fat dietMetabolic disordersHigh-fat diet-induced obesityBody mass index valuesInhibition of NogoSerum proinflammatory cytokinesDiet-induced obesityInfiltration of macrophagesType 2 diabetesWT littermate control miceLittermate control miceEffects of NogoMass index valuesBrown adipose tissueProtect miceNormal chowControl miceProinflammatory cytokinesInsulin resistanceObesity treatmentRisk factorsLipid profileCardiovascular diseaseProtein NogoObesity
2021
Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis
Sanchez J, Jiao J, Kwan S, Veillon L, Warmoes M, Tan L, Odewole M, Rich N, Wei P, Lorenzi P, Singal A, Beretta L. Lipidomic Profiles of Plasma Exosomes Identify Candidate Biomarkers for Early Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prevention Research 2021, 14: canprevres.0612.2021. PMID: 34253566, PMCID: PMC8546639, DOI: 10.1158/1940-6207.capr-20-0612.Peer-Reviewed Original ResearchConceptsLogistic regression analysisHCC exosomesCirrhotic patientsEarly detectionHepatocellular carcinomaCandidate biomarkersTumor developmentNoninvasive diagnostic biomarkersRegression analysisHCC surveillanceLipid profileEndocannabinoid signalingHCC diagnosisNovel biomarkersLipid classesDiagnostic biomarkersPlasma exosomesLipidomic profilesGlycerophospholipid metabolismHCCPatientsBiomarkersUntargeted lipidomicsCarcinomaDifferential effects
2020
Incident diabetes complications among women with type 1 diabetes based on parity
Polsky S, Foster NC, DuBose SN, Agarwal S, Lyons S, Peters AL, Uwaifo GI, DiMeglio LA, Sherr JL, Levy CJ. Incident diabetes complications among women with type 1 diabetes based on parity. The Journal Of Maternal-Fetal & Neonatal Medicine 2020, 35: 4629-4634. PMID: 33280471, DOI: 10.1080/14767058.2020.1858278.Peer-Reviewed Original ResearchConceptsType 1 diabetesParous womenNulliparous womenDiabetes complicationsRisk factorsHigher Body Mass IndexAdverse lipid profileTriglyceride/HDLOverweight/obesityBody mass indexAdvanced nephropathyMass indexT1D ExchangeFirst pregnancyPregnant womenChildbirth QuestionnaireLipid profileCardiovascular diseaseComplicationsWomenHypertensionYear 5Further studiesSignificant differencesDiabetesClinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy
Jones SA, McGovern M, Lidove O, Giugliani R, Mistry PK, Dionisi-Vici C, Munoz-Rojas MV, Nalysnyk L, Schecter AD, Wasserstein M. Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Molecular Genetics And Metabolism 2020, 131: 116-123. PMID: 32616389, DOI: 10.1016/j.ymgme.2020.06.008.Peer-Reviewed Original ResearchConceptsAcid sphingomyelinase deficiencyDisease burdenLipid profilePrevalent clinical featuresRespiratory-related complicationsAtherogenic lipid profileAbnormal lipid profileProgressive lung diseaseLung diffusion capacityEnzyme replacement therapyRare lysosomal storage disorderDiverse disease spectrumDegree of abnormalityNiemann-Pick diseaseLysosomal storage disorderLung functionClinical featuresClinical parametersReplacement therapyChronic formClinical burdenLung diseaseNeurovisceral diseaseSpleen volumeLiver fibrosis
2019
Association between APOE polymorphisms and lipid profile in Mexican Amerindian population
Martínez‐Magaña J, Genis‐Mendoza A, Tovilla‐Zarate C, González‐Castro T, Juárez-Rojop IE, Hernández‐Díaz Y, Martinez‐Hernandez A, Garcia‐Ortíz H, Orozco L, López‐Narvaez M, Nicolini H. Association between APOE polymorphisms and lipid profile in Mexican Amerindian population. Molecular Genetics & Genomic Medicine 2019, 7: e958. PMID: 31557780, PMCID: PMC6825948, DOI: 10.1002/mgg3.958.Peer-Reviewed Original ResearchConceptsLDL-C levelsHDL-C levelsLipid profileLipoprotein cholesterolTotal cholesterolBiochemical variablesHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolHigher HDL-C levelsMexican Amerindian populationsAPOE e4 carriersDifferent APOE allelesObese individualsGene allelesApoE E3E2 alleleApoE isoformsAPOE polymorphismE4 alleleApolipoprotein EAnthropometric measurementsKruskal-Wallis testAPOE allelesLipid metabolismE3 alleleReduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19)
Mehal W, Dioletis E, Paiva R, Secor E, Weiss T, Fields M, Ouyang X, Ali A. Reduction in Serum Cholesterol in Subjects Consuming the Fermented Soy Beverage Q-CAN® Plus (P06-118-19). Current Developments In Nutrition 2019, 3: nzz031.p06-118-19. PMCID: PMC6576748, DOI: 10.1093/cdn/nzz031.p06-118-19.Peer-Reviewed Original ResearchTotal cholesterol levelsLDL cholesterolCholesterol levelsLipid parametersTotal cholesterolVisit 1Obese individualsPercentage changeTreatment total cholesterolSerum lipid profileMethods Prospective studyLDL cholesterol valuesPost treatmentVisit 7Clinic visitsHDL cholesterolObese subjectsLean subjectsProspective studyVisit 3Hypolipidemic effectsSerum cholesterolLean individualsLipid profileVisit 8Chronic maternal cortisol excess during late gestation leads to metabolic alterations in the newborn heart
Walejko J, Antolic A, Koelmel J, Garrett T, Edison A, Keller-Wood M. Chronic maternal cortisol excess during late gestation leads to metabolic alterations in the newborn heart. AJP Endocrinology And Metabolism 2019, 316: e546-e556. PMID: 30620638, PMCID: PMC6459297, DOI: 10.1152/ajpendo.00386.2018.Peer-Reviewed Original ResearchConceptsNewborn heartLate gestationCortisol altersMaternal cortisolCardiac arrhythmiasFetal cardiac arrhythmiasMaternal serum specimensCortisol excessFetal exposureMaternal serumFetal metabolismCardiac metabolitesAbnormal elevationExcess cortisolLipid profileChronic increaseFetal serumGestation leadMetabolic alterationsSerum specimensHeart specimensFetal heartLipid metabolitesGlycerophospholipid metabolismCortisol
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply